Current update on retinopathy of prematurity: Screening and treatment

Current Opinion in Pediatrics

Volumn 23, Issue 2, 2011, Pages 173-178

  Chen, Jing ^a   Stahl, Andreas ^a,b   Hellstrom, Ann ^c   Smith, Lois E ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

insulin like growth factor; laser photocoagulation; postnatal weight gain; retinopathy of prematurity; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; OMEGA 3 FATTY ACID; RECOMBINANT ERYTHROPOIETIN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; WNT PROTEIN;

ANEMIA; BLEEDING; BODY WEIGHT; DISEASE SEVERITY; DRUG TOLERANCE; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC PREDISPOSITION; HUMAN; LASER COAGULATION; MYOPIA; NONHUMAN; OUTCOME ASSESSMENT; PERINATAL PERIOD; PREDICTION; PREMATURITY; PRIORITY JOURNAL; RETROLENTAL FIBROPLASIA; REVIEW; RISK ASSESSMENT; SCREENING; STRABISMUS; SURVIVAL; VISION; VISUAL ACUITY; VITRECTOMY; WEIGHT GAIN;

EID: 79953859312     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e3283423f35     Document Type: Review

References (64)

1. Silverman W. Retrolental fibroplasia: a modern parable. New York: Grune and Stratton; 1980.
2. Terry TL. Retrolental fibroplasia in the premature infant: V. Further studies on fibroplastic overgrowth of the persistent tunica vasculosa lentis. Trans Am Ophthalmol Soc 1944; 42:383-396.
3. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia; a clinical approach. Med J Aust 1951; 2:48-50.
4. Patz A, Hoeck LE, De La Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia. I. Nursery observations. Am J Ophthalmol 1952; 35:1248-1253.
5. Kinsey VE, Arnold HJ, Kalina RE, et al. PaO2 levels and retrolental fibroplasia: a report of the cooperative study. Pediatrics 1977; 60:655-668. (Pubitemid 8242419)
6. Flynn JT. Acute proliferative retrolental fibroplasia: multivariate risk analysis. Trans Am Ophthalmol Soc 1983; 81:549-591. (Pubitemid 14111611)
7. Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol 2003; 8:469-473. (Pubitemid 37474717)
8. Tasman W, Patz A, McNamara JA, et al. Retinopathy of prematurity: the life of a lifetime disease. Am J Ophthalmol 2006; 141:167-174.
9. Lutty GA, Chan-Ling T, Phelps DL, et al. Proceedings of the Third International SymposiumonRetinopathy of Prematurity: an update onROPfromthe lab to the nursery (November 2003, Anaheim, California). Mol Vis 2006; 12:532-580.
10. Blanco CL, Baillargeon JG, Morrison RL, Gong AK. Hyperglycemia in extremely low birth weight infants in a predominantly Hispanic population and related morbidities. J Perinatol 2006; 26:737-741. (Pubitemid 44811507)
11. Ertl T, Gyarmati J, Gaal V, Szabo I. Relationship between hyperglycemia and retinopathy of prematurity in very low birth weight infants. Biol Neonate 2006; 89:56-59. (Pubitemid 43087509)
12. Garg R, Agthe AG, Donohue PK, Lehmann CU. Hyperglycemia and retinopathy of prematurity in very low birth weight infants. J Perinatol 2003; 23:186-194. (Pubitemid 36656517)
13. Hellstrom A, Engstrom E, Hard AL, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003; 112:1016-1020. (Pubitemid 37339551)
14. Lofqvist C, Chen J, Connor KM, et al. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci U S A 2007; 104:10589-10594. (Pubitemid 47185709)
15. Lofqvist C, Engstrom E, Sigurdsson J, et al. Postnatal head growth deficit among premature infants parallels retinopathy of prematurity and insulin-like growth factor-1 deficit. Pediatrics 2006; 117:1930-1938. (Pubitemid 46071236)
16. Wu WC, Ong FS, Kuo JZ, et al. Retinopathy of prematurity and maternal age. Retina 2010; 30:327-331.
17. Holmstrom G, Thomassen P, Broberger U. Maternal risk factors for retinopathy of prematurity: a population-based study. Acta Obstet Gynecol Scand 1996; 75:628-635. (Pubitemid 26302258)
18. Shastry BS. Genetic susceptibility to advanced retinopathy of prematurity (ROP). J Biomed Sci 2010; 17:69.
19. Bizzarro MJ, Hussain N, Jonsson B, et al. Genetic susceptibility to retinopathy of prematurity. Pediatrics 2006; 118:1858-1863. (Pubitemid 46393666)
20. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127:469-480.
21. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20:781-810. (Pubitemid 39488658)
22. Moon RT. Wnt/beta-catenin pathway. Sci STKE 2005; 2005:cm1.
23. Hutcheson KA, Paluru PC, Bernstein SL, et al. Norrie disease gene sequence variants in an ethnically diverse population with retinopathy of prematurity. Mol Vis 2005; 11:501-508. (Pubitemid 41410228)
24. Dickinson JL, Sale MM, Passmore A, et al. Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity. Clin Experiment Ophthalmol 2006; 34:682-688. (Pubitemid 44363620)
25. Hiraoka M, Berinstein DM, Trese MT, Shastry BS. Insertion and deletion mutations in the dinucleotide repeat region of the Norrie disease gene in patients with advanced retinopathy of prematurity. J Hum Genet 2001; 46:178-181. (Pubitemid 32435599)
26. Kim JH, Yu YS, Kim J, Park SS. Mutations of the Norrie gene in Korean ROP infants. Kor J Ophthalmol 2002; 16:93-96.
27. Shastry BS, Pendergast SD, Hartzer MK, et al. Identification of missense mutations in the Norrie disease gene associated with advanced retinopathy of prematurity. Arch Ophthalmol 1997; 115:651-655.
28. MacDonald ML, Goldberg YP, Macfarlane J, et al. Genetic variants of frizzled-4 gene in familial exudative vitreoretinopathy and advanced retinopathy of prematurity. Clin Genet 2005; 67:363-366. (Pubitemid 40424836)
29. Ells A, Guernsey DL, Wallace K, et al. Severe retinopathy of prematurity associated with FZD4 mutations. Ophthalmic Genet 2010; 31:37-43. This is a genetic study that identifies mutation of frizzled4, a receptor for Wnt signaling pathway, associated with severe retinopathy of prematurity.
30. Wu C, Vanderveen DK, Hellstrom A, et al. Longitudinal postnatal weight measurements for the prediction of retinopathy of prematurity. Arch Ophthalmol 2010; 128:443-447.
31. Lofqvist C, Hansen-Pupp I, Andersson E, et al. Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulin-like growth factor I. Arch Ophthalmol 2009; 127:622-627.
32. Hellstrom A, Hard AL, Engstrom E, et al. Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics 2009; 123:e638-e645. This study utilizes postnatal weight gain alone as clinical criteria to successfully predict ROP development.
33. Perez-Munuzuri A, Fernandez-Lorenzo JR, Couce-Pico ML, et al. Serum levels of IGF1 are a useful predictor of retinopathy of prematurity. Acta Paediatr 2010; 99:519-525.
34. Pieh C, Kruger M, Lagreze WA, et al. Plasma sE-selectin in premature infants: a possible surrogate marker of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2010; 51:3709-3713.
35. Ng EY, Connolly BP, McNamara JA, et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. Ophthalmology 2002; 109:928-934; discussion 935.
36. Connolly BP, Ng EY, McNamara JA, et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome. Ophthalmology 2002; 109:936-941. (Pubitemid 34465229)
37. Parvaresh MM, Modarres M, Falavarjani KG, et al. Transscleral diode laser retinal photocoagulation for the treatment of threshold retinopathy of prematurity. J AAPOS 2009; 13:535-538. This study compares trans-scleral diode laser photocoagulation with traditional transpupillary laser treatment for ROP treatment.
38. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46:1473-1480. (Pubitemid 27369086)
39. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995; 92:10457-10461.
40. Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999; 5:1390-1395.
41. Sato T, Kusaka S, Shimojo H, Fujikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology 2009; 116:2165-2169. In this study, 27 cytokines including VEGF and erythropoietin were assessed in the vitreous fluid of patients with ROP.
42. Sonmez K, Drenser KA, Capone A Jr, Trese MT. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008; 115:1065-1070 e1.
43. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 2009; 116:1599-1603. In this study, erythropoietin was found elevated in the vitreous fluid of patients with ROP. The increase of erythropoietin is associated with VEGF elevation.
44. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-1444. (Pubitemid 44511558)
45. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419-1431. (Pubitemid 44511557)
46. Nonobe NI, Kachi S, Kondo M, et al. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab. Retina 2009; 29:579-585. In this study, VEGF levels in eyes of ROP patients were measured before and after treatment with anti-VEGF bevacizumab, showing correlation of VEGF with ROP and with treatment.
47. Law JC, Recchia FM, Morrison DG, et al. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS 2010; 14:6-10.
48. Lee JY, Chae JB, Yang SJ, et al. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol 2010; 248:1257-1262.
49. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol 2009; 148:536-543 e2. This is a systematic review of the literature regarding the use of bevacizumab, an anti-VEGF therapy for ROP treatment.
50. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008; 118:526-533. (Pubitemid 351206543)
51. Chen J, Connor KM, Aderman CM, et al. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci 2009; 50:1329-1335.
52. Jaquet K, Krause K, Tawakol-Khodai M, et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002; 64:326-333.
53. Suh KK, Dunbar JA, Liu A, et al. Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model. J Aapos 2008; 12:233-238. (Pubitemid 351853461)
54. Shah N, Jadav P, Jean-Baptiste D, et al. The effect of recombinant human erythropoietin on the development of retinopathy of prematurity. Am J Perinatol 2010; 27:67-71.
55. Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A 2001; 98:5804-5808. (Pubitemid 32435723)
56. Smith LE, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997; 276:1706-1709. (Pubitemid 27421979)
57. Connor KM, Sangiovanni JP, Lofqvist C, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007; 13:868-873. (Pubitemid 47038185)
58. Hansen-Pupp I, Hellstrom-Westas L, Cilio CM, et al. Inflammation at birth and the insulin-like growth factor system in very preterm infants. Acta Paediatr 2007; 96:830-836. (Pubitemid 46846893)
59. Lofqvist C, Niklasson A, Engstrom E, et al. A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. Pediatr Res 2009; 65:574-579. This is a phase I clinical study on supplementing IGF and IGFBP3 to preterm infants.
60. Hellstrom A. Insulin-like growth factor I (IGF-I) in the prevention of complications of preterm birth. http://wwwclinicaltrialsgov. [Accessed 18 October 2010]
61. Stahl A, Sapieha P, Connor KM, et al. Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy. Circ Res 2010; 107:495-500.
62. Salvin JH, Lehman SS, Jin J, Hendricks DH. Update on retinopathy of prematurity: treatment options and outcomes. Curr Opin Ophthalmol 2010; 21:329-334.
63. Good WV, Hardy RJ, Dobson V, et al. Final visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol 2010; 128:663-671. This is the study of final visual outcome from the early treatment of ROP group.
64. Christiansen SP, Dobson V, Quinn GE, et al. Progression of type 2 to type 1 retinopathy of prematurity in the Early Treatment for Retinopathy of Prematurity Study. Arch Ophthalmol 2010; 128:461-465.